Based on the high co-morbidity of diabetes and NAFLD and the pathways which connect these diseases, the impact of insulin treatment is also under investigation as potentially yielding NAFLD treatment benefits. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.